We have also tested a combinatorial AND-gated tumor targeting approach with the TAA PSCA and PD-L1, predicting a versatile and precise application of PD-L1 targeting by the RevCAR system in a wide range of solid tumor entities. Here, CD274 is linked to neoplasm.